培美曲塞、顺铂联合重组人血管内皮抑制素治疗肺腺癌

目的观察培美曲塞、顺铂联合重组人血管内皮抑制素注射液（恩度）治疗肺腺癌的疗效与安全性。方法选择经病理及细胞学诊断明确的晚期肺腺癌初治患者52例，根据住院号随机分为观察组27例，对照组25例，观察组给予培美曲塞＋顺铂联合恩度治疗，对照组仅给予培美曲塞＋顺铂治疗，评价两组疗效及安全性。结果观察组客观有效率（48．1％）明显高于对照组（36．0％）（x2=7．82，P〈0．05）；观察组疾病控制率（92．6％）明显高于对照组（84．0％）（x2=4．05，P〈0．05）；观察组中位肿瘤进展时间（7．5个月）明显长于对照组（5个月）（t=5．71，P〈0．05）；两组在治疗期间均出现相似的不良反应，主要为白细胞减少、血红蛋白减少、血小板减少、恶心呕吐、便秘、心律失常、出血、乏力等，两组在不良反应分级情况差异均无统计学意义（均P〉0．05）。结论培美曲塞、顺铂联合恩度治疗肺腺癌疗效较单用化疗药疗效显著，且未增加不良反应，具有安全性，可作为肺腺癌的一线用药。

Pemetrexed plus cisplatin combined with recombinant human endostatin in the treatment of lung adenocarci-noma

Objective To observe the curative effect and security of pemetrexed plus cisplatin combined with recombinant human endostatin in the treatment of lung adenocarcinoma. Methods 52 patients with advanced lung adenocarcinoma confirmed by pathologic and cytologic diagnosis were included in this study. According to the number of hospitalized, the patients were randomly divided into the observation group （27 cases） and the control group （25 cases）. The observation group was given pemetrexed plus cisplatin combined with recombinant human endostatin, and the control group was only given pemetrexed plus cisplatin. The curative effect and safety of two groups were evalua- ted. Results The objective response rate of observation group was 48.1% ,which was obviously higher than 36.0% of control group （x2 = 7.82, P 〈 0.05 ）. Disease control rate of observation group （92.6%） was obviously higher than that of control group （ 84.0% ） （ x2 = 4.05, P 〈 0.05 ）. Time to progression in observation group was 7.5 months,which was significantly longer than 5 months in control group （ t = 5.71 ,P 〈 0.05 ）. Two groups had similar adverse reactions during treatment, mainly including white blood cells reduce, hemoglobin, thrombocytopenia, nausea, vomiting, constipation, arrhythmia, hemorrhage, fatigue, etc. , there was no significant difference in adverse reactions grading situation in two groups （ P 〉 0.05 ）. Conclusion The curative effect of pemetrexed plus cisplatin combined with recombinant human endostatin in the treatment of lung adenocarcinoma is distinct, not increase adverse reactions, and it is safe,which can be used as first-line drug in patients with lung adenocarcinoma.